Literature DB >> 2981456

DNA sequence of the early E3 transcription unit of adenovirus 5.

C Cladaras, W S Wold.   

Abstract

The DNA sequence of the early E3 transcription unit of adenovirus 5 (Ad5) has been determined and it has been compared to Ad2, as published previously [J. Hérissé, G. Courtois, and F. Galibert (1980), Nucl. Acids Res. 8, 2173-2192; J. Hérissé and F. Galibert (1981), Nucl. Acids Res. 9, 1229-1240]. The E3 regions of Ad5 and Ad2 are quite homologous despite being nonessential for Ad growth in cultured cells. The major differences are "gaps" that exist either in Ad5 or Ad2 in intergenic regions. The conservation of sequences suggests that E3 plays a beneficial role in natural infection of humans. E3 appears to encode about seven to nine proteins; based on sequence, seven of these may be membrane proteins. Thus, E3 may be a transcription unit devoted to the synthesis of membrane proteins. The E3 genes lie essentially one after the other along the genome, and which gene is expressed from a given primary transcript is determined by the choice of the 3' end site and the 5' and 3' splice sites. Almost all E3 mRNAs contain nonfunctional AUGs that are 5' to the initiation codon. Codon usage is nonrandom. Although the CG dinucleotide frequency is low, CG clusters exist in the promoter and other regions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981456     DOI: 10.1016/0042-6822(85)90443-x

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  51 in total

1.  Map of cis-acting sequences that determine alternative pre-mRNA processing in the E3 complex transcription unit of adenovirus.

Authors:  H A Brady; A Scaria; W S Wold
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

2.  The 11,600-MW protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection.

Authors:  A E Tollefson; A Scaria; S K Saha; W S Wold
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

3.  Adenovirus E3-6.7K protein is required in conjunction with the E3-RID protein complex for the internalization and degradation of TRAIL receptor 2.

Authors:  Drew L Lichtenstein; Konstantin Doronin; Karoly Toth; Mohan Kuppuswamy; William S M Wold; Ann E Tollefson
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

4.  Identification of a specific exon sequence that is a major determinant in the selection between a natural and a cryptic 5' splice site.

Authors:  L Domenjoud; H Gallinaro; L Kister; S Meyer; M Jacob
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

5.  In vivo splicing of the premRNAs from early region 3 of adenovirus-2: the products of cleavage at the 5' splice site of the common intron.

Authors:  A Sittler; H Gallinaro; M Jacob
Journal:  Nucleic Acids Res       Date:  1986-02-11       Impact factor: 16.971

6.  Homologous recombination in E3 genes of human adenovirus species D.

Authors:  Gurdeep Singh; Christopher M Robinson; Shoaleh Dehghan; Morris S Jones; David W Dyer; Donald Seto; James Chodosh
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

7.  A 10,400-molecular-weight membrane protein is coded by region E3 of adenovirus.

Authors:  A E Tollefson; P Krajcsi; S P Yei; C R Carlin; W S Wold
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

8.  In vitro assessments of the genetic stability of a live recombinant human adenovirus vaccine against rabies.

Authors:  C Lutze-Wallace; T Sapp; M Sidhu; A Wandeler
Journal:  Can J Vet Res       Date:  1995-04       Impact factor: 1.310

9.  Genetic organization, size, and complete sequence of early region 3 genes of human adenovirus type 41.

Authors:  H Y Yeh; N Pieniazek; D Pieniazek; R B Luftig
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Distinct domains in the adenovirus E3 RIDalpha protein are required for degradation of Fas and the epidermal growth factor receptor.

Authors:  Tom A Zanardi; Soonpin Yei; Drew L Lichtenstein; Ann E Tollefson; William S M Wold
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.